GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Shineway Pharmaceutical Group Ltd (HKSE:02877) » Definitions » Change In Receivables

China Shineway Pharmaceutical Group (HKSE:02877) Change In Receivables : HK$0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is China Shineway Pharmaceutical Group Change In Receivables?

China Shineway Pharmaceutical Group's change in receivables for the quarter that ended in Dec. 2024 was HK$0 Mil. It means China Shineway Pharmaceutical Group's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

China Shineway Pharmaceutical Group's change in receivables for the fiscal year that ended in Dec. 2024 was HK$55 Mil. It means China Shineway Pharmaceutical Group's Accounts Receivable declined by HK$55 Mil from Dec. 2023 to Dec. 2024 .

China Shineway Pharmaceutical Group's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$970 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. China Shineway Pharmaceutical Group's Days Sales Outstanding for the six months ended in Dec. 2024 was 97.99.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. China Shineway Pharmaceutical Group's liquidation value for the six months ended in Dec. 2024 was HK$5,342 Mil.


China Shineway Pharmaceutical Group Change In Receivables Historical Data

The historical data trend for China Shineway Pharmaceutical Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Shineway Pharmaceutical Group Change In Receivables Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -110.56 -82.00 -177.23 -318.01 55.26

China Shineway Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

China Shineway Pharmaceutical Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Shineway Pharmaceutical Group  (HKSE:02877) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

China Shineway Pharmaceutical Group's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=969.569/1805.805*91
=97.99

2. In Ben Graham's calculation of liquidation value, China Shineway Pharmaceutical Group's accounts receivable are only considered to be worth 75% of book value:

China Shineway Pharmaceutical Group's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6929.376-2748.856+0.75 * 969.569+0.5 * 868.22
=5,342

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Shineway Pharmaceutical Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of China Shineway Pharmaceutical Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


China Shineway Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. It is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.
Executives
Bh Corporate Services Ltd 2301 Trustee
Bodnar-horvath Kwai Yung Helen 2202 Interest of your spouse
Bodnar-horvath Nicholas Eugene Francis 2201 Interest of corporation controlled by you
Forway Investment Limited 2101 Beneficial owner
Li Zhenjiang 2307 Founder of a discretionary trust who can infl

China Shineway Pharmaceutical Group Headlines

No Headlines